Avoid Excessive Use of Trelegy Ellipta and Avoid Use with Other Long-acting Beta2-agonists Do not exceed the recommended dose. Clinically significant cardiovascular effects and fatalities have ...
The FDA has approved GlaxoSmithKline’s Trelegy Ellipta inhaler for asthma in adults, adding to its existing use in chronic obstructive pulmonary disease (COPD), stealing a march on rivals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback